Tizanidine
- Product NDC
- 53002-1418
- 11-digit product format
- 530021418
- Labeler code
- 53002
- Product ID
- 53002-1418_342a4d5d-638b-4b6c-a42b-08623a1ef571
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Tizanidine
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- RPK Pharmaceuticals, Inc.
- Application
- ANDA091283
- Marketing category
- ANDA
- Marketing start
- 2013-04-01
- Marketing end
- 0000-00-00
- Substance
- TIZANIDINE HYDROCHLORIDE
- Active strength
- 2 mg/1
- Pharmacologic classes
- Adrenergic alpha2-Agonists [MoA],Central alpha-2 Adrenergic Agonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2021-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
NDC, Effective, Action table| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|
| 53002-1418-3 | 2025-01-30 | C162847 | 48780-1 | f386c64a-1d4d-0266-e053-dadaa90a7c1a | These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP. TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral use Initial U.S. Approval:1996 |
| 53002-1418-5 | 2025-01-30 | C162847 | 48780-1 | f386c64a-1d4d-0266-e053-dadaa90a7c1a | These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP. TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral use Initial U.S. Approval:1996 |
| 53002-1418-3 | 2023-06-07 | C162847 | 48780-1 | f386c64a-1d4d-0266-e053-dadaa90a7c1a | These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP. TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral use Initial U.S. Approval:1996 |
| 53002-1418-5 | 2023-06-07 | C162847 | 48780-1 | f386c64a-1d4d-0266-e053-dadaa90a7c1a | These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP. TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral use Initial U.S. Approval:1996 |
| 53002-1418-3 | 2023-01-30 | C162847 | 48780-1 | f386c64a-1d4d-0266-e053-dadaa90a7c1a | These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP. TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral use Initial U.S. Approval:1996 |
| 53002-1418-5 | 2023-01-30 | C162847 | 48780-1 | f386c64a-1d4d-0266-e053-dadaa90a7c1a | These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP. TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral use Initial U.S. Approval:1996 |
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 53002-1418-3 | Tizanidine | 30 in 1 BOTTLE | TABLET | 30 | | 3 |
| 53002-1418-5 | Tizanidine | 15 in 1 BOTTLE | TABLET | 15 | | 3 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 53002-1418 | TIZANIDINE TABLET [RPK PHARMACEUTICALS, INC.] | 3 | Legacy NDC, 2 package rows | 20230609_747b8a4f-3683-4b95-8cca-88b9be3b3526.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 53002-1418-3 | 53002141803 | 30 TABLET in 1 BOTTLE (53002-1418-3) | 30 tablet | 2019-01-01 | 0000-00-00 | No | No | Current |
| 53002-1418-5 | 53002141805 | 15 TABLET in 1 BOTTLE (53002-1418-5) | 15 tablet | 2019-01-01 | 0000-00-00 | No | No | Current |